Tempus ECG-AF vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by Tempus AI, Inc.
VS
by Elucid

AI Verdict

Both Tempus ECG-AF and ElucidVivo A.3 are FDA-cleared AI tools aimed at cardiovascular care, but they address distinct clinical needs. Tempus ECG-AF focuses on predicting the risk of atrial fibrillation from ECGs, while ElucidVivo A.3 provides quantitative analysis of arterial plaque from CT angiography for atherosclerosis management. Therefore, their direct comparability is limited, as they serve different diagnostic pathways within cardiology.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if you need to proactively identify older patients at increased risk of developing new-onset atrial fibrillation within the next 12 months. This tool is ideal for screening individuals aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, using standard 12-lead ECGs to support earlier intervention and follow-up.

View Tempus ECG-AF →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography to optimize treatment decisions for atherosclerosis patients. This system is best suited for stratifying patients by objectively measuring lipid-rich necrotic core, matrix, and calcifications, and providing 3D visualizations to guide cardiovascular care.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Tempus ECG-AF ElucidVivo A.3
Pricing Contact vendor Unknown
Deployment Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. Cloud and on-premise secure deployment.
BAA Available Yes AI-estimated Unknown
FDA Status Yes AI-estimated Cleared AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Tempus ECG-AF

Tempus ECG-AF is designed to integrate seamlessly into existing ECG platforms and EHRs without a dedicated user interface, minimizing disruption to clinical workflows. This approach offers a lower friction adoption compared to ElucidVivo A.3, which, while integrating with PACS/EMR, implies a separate software application with its own user interface.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 provides a more profound and predictive clinical insight through quantitative analysis of arterial plaque composition and stability, validated against histology, and deriving fractional flow reserve (FFRct). This enables advanced patient stratification and has demonstrated a 40% improvement in predictive accuracy for major adverse neurologic events, offering a higher level of impact on patient management compared to Tempus ECG-AF's risk stratification.

Pricing & Value

ElucidVivo A.3

While Tempus ECG-AF has an established CMS reimbursement path, ElucidVivo A.3 has recently secured a Category I CPT code (75577) with a significantly higher national average payment amount ($1,012 for imaging centers/physician offices, $951 for hospital outpatient settings), effective January 1, 2026. This, coupled with widespread coverage from major public and private payors, provides a more transparent and attractive financial value proposition.

Enterprise Readiness

Tempus ECG-AF

Tempus ECG-AF explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical for enterprise adoption in healthcare. ElucidVivo A.3's compliance is implied by its FDA clearance and intended use, but explicit statements regarding HIPAA and BAA are not provided in the available information, giving Tool A a clear advantage in demonstrating enterprise readiness.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates greater innovation by offering highly specialized, quantitative analysis of arterial plaque composition and stability, including histological validation and the derivation of FFRct. This provides predictive insights for personalized atherosclerosis management, moving beyond traditional diagnostic assistance to a deeper understanding of disease pathology.

Support & Docs

Tempus ECG-AF

Tempus AI provides clear customer support channels, including phone and email, with specified operating hours, and mentions offering necessary manuals and forms. Elucid Bioimaging provides general contact information but lacks explicit details on dedicated customer support resources, operating hours, or comprehensive documentation, making Tempus ECG-AF's support framework more robust and transparent.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Tempus ECG-AF ElucidVivo A.3
Name Tempus ECG-AF ElucidVivo A.3
Company Tempus AI, Inc. Elucid Bioimaging
Primary Function/Analysis Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months. Provides quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions.
Target Patient Population/Data Input Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; 12-lead ECG recordings. Patients with atherosclerosis; CT angiography images.
Key Technology AI-based algorithm for 12-lead ECG analysis. AI-powered medical image analysis system for quantitative analysis of arterial plaque.
Specialties Cardiology, Geriatrics, Internal Medicine Cardiology, Radiology, Vascular Surgery

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and ElucidVivo A.3.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

Tempus ECG-AF is a software solution integrated into healthcare facility systems with advanced cardiology algorithms, designed to work with existing ECG platforms and EHRs to enable advanced AI deployment and insights within clinical workflows. ElucidVivo A.3 is a software application that integrates with PACS/EMR, following typical clinical workflow patterns to process, review, and analyze digital images.
Tempus ECG-AF is an FDA-cleared AI-based algorithm trained on over 1.5 million ECGs from over 500,000 patients, demonstrating a sensitivity of 31% and specificity of 92% for classifying patients at increased risk of AF within 12 months. ElucidVivo A.3 is an FDA-cleared AI-powered system that provides quantitative analysis of arterial plaque composition and stability from CT angiography, with its plaque characteristics validated against histology.
Tempus ECG-AF is intended for patients aged 65 or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery, to identify increased risk of developing AF within 12 months, supporting earlier identification and follow-up. ElucidVivo A.3 assists in atherosclerosis patient stratification and optimizes treatment decisions by offering detailed visualization and measurement of plaque characteristics, including Lipid-Rich Necrotic Core, from CT angiography.
While not explicitly detailed, Tempus ECG-AF analyzes standard 12-lead ECGs and is designed for integration into existing cardiology workflows, suggesting a potentially straightforward adoption for interpreting risk scores. ElucidVivo A.3 provides detailed quantitative analysis and 3D visualizations of plaque, which may require some initial training for physicians to fully leverage its advanced imaging interpretation and FFRct derivation capabilities.
The provided information does not explicitly detail audit-trail features for either Tempus ECG-AF or ElucidVivo A.3. However, Tempus states it maintains strict access controls, ensuring only authorized personnel with specific, audited roles can interact with their systems.
Tempus ECG-AF is a software solution integrated into healthcare facility systems, with Northwestern Medicine being the first major healthcare institution to integrate it into clinical workflows, suggesting multi-site deployment would involve standard IT infrastructure planning. ElucidVivo A.3, as a software application integrating with PACS/EMR, would similarly require careful planning for network infrastructure, data access, and consistent user training across multiple sites.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.